Hyemyung Seo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7712218/publications.pdf

Version: 2024-02-01

47	2,775	218381	214527
papers	citations	26 h-index	47 g-index

48	48	48	4357
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Spotting-based differentiation of functional dopaminergic progenitors from human pluripotent stem cells. Nature Protocols, 2022, , .	5.5	6
2	Analysis of multiâ€omics data on the relationship between epigenetic changes and nervous system disorders caused by exposure to environmentally harmful substances. Environmental Toxicology, 2022, 37, 802-813.	2.1	5
3	Brain cells derived from Alzheimerâ€™s disease patients have multiple specific innate abnormalities in energy metabolism. Molecular Psychiatry, 2021, 26, 5702-5714.	4.1	54
4	Dysfunction of X-linked inhibitor of apoptosis protein (XIAP) triggers neuropathological processes via altered p53 activity in Huntingtonâ€™s disease. Progress in Neurobiology, 2021, 204, 102110.	2.8	8
5	Matrix Metalloproteinase-8 Inhibitor Ameliorates Inflammatory Responses and Behavioral Deficits in LRRK2 G2019S Parkinson's Disease Model Mice. Biomolecules and Therapeutics, 2021, 29, 483-491.	1.1	4
6	Modulation of SETDB1 activity by APQ ameliorates heterochromatin condensation, motor function, and neuropathology in a Huntingtonâ€™s disease mouse model. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 856-868.	2.5	7
7	Iroquois Homeobox Protein 2 Identified as a Potential Biomarker for Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 3455.	1.8	7
8	Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinsonâ€™s Disease. New England Journal of Medicine, 2020, 382, 1926-1932.	13.9	298
9	Human autologous iPSCâ€“derived dopaminergic progenitors restore motor function in Parkinsonâ€™s disease models. Journal of Clinical Investigation, 2020, 130, 904-920.	3.9	102
10	HDAC Inhibition by Valproic Acid Induces Neuroprotection and Improvement of PD-like Behaviors in LRRK2 R1441G Transgenic Mice. Experimental Neurobiology, 2019, 28, 504-515.	0.7	31
11	Alpha-Synuclein Suppresses Retinoic Acid-Induced Neuronal Differentiation by Targeting the Glycogen Synthase Kinase-3Î²/Î²-Catenin Signaling Pathway. Molecular Neurobiology, 2018, 55, 1607-1619.	1.9	14
12	Increase in anti-apoptotic molecules, nucleolin, and heat shock protein 70, against upregulated LRRK2 kinase activity. Animal Cells and Systems, 2018, 22, 273-280.	0.8	9
13	Cell-Penetrating Peptide-Patchy Deformable Polymeric Nanovehicles with Enhanced Cellular Uptake and Transdermal Delivery. Biomacromolecules, 2018, 19, 2682-2690.	2.6	39
14	Oxidized DJ-1 Levels in Urine Samples as a Putative Biomarker for Parkinsonâ€™s Disease. Parkinson's Disease, 2018, 2018, 1-9.	0.6	13
15	Age-associated bimodal transcriptional drift reduces intergenic disparities in transcription. Aging, 2018, 10, 789-807.	1.4	15
16	Suppression of neuroinflammation by matrix metalloproteinase-8 inhibitor in aged normal and LRRK2 G2019S Parkinson's disease model mice challenged with lipopolysaccharide. Biochemical and Biophysical Research Communications, 2017, 493, 879-886.	1.0	18
17	Age-associated chromatin relaxation is enhanced in Huntingtonâ€™s disease mice. Aging, 2017, 9, 803-822.	1.4	24
18	MiR-126 Regulates Growth Factor Activities and Vulnerability to Toxic Insult in Neurons. Molecular Neurobiology, 2016, 53, 95-108.	1.9	48

#	Article	IF	Citations
19	G2385R and I2020T Mutations Increase LRRK2 GTPase Activity. BioMed Research International, 2016, 2016, 1-8.	0.9	28
20	Gene therapy by proteasome activator, PA28Î³, improves motor coordination and proteasome function in Huntingtonâ€™s disease YAC128 mice. Neuroscience, 2016, 324, 20-28.	1.1	36
21	Leucine-rich repeat kinase 2 exacerbates neuronal cytotoxicity through phosphorylation of histone deacetylase 3 and histone deacetylation. Human Molecular Genetics, 2016, 26, ddw363.	1.4	17
22	Î²-Lapachone increases phase II antioxidant enzyme expression via NQO1-AMPK/PI3K-Nrf2/ARE signaling in rat primary astrocytes. Free Radical Biology and Medicine, 2016, 97, 168-178.	1.3	44
23	Neuroanatomical Visualization of the Impaired Striatal Connectivity in Huntingtonâ€™s Disease Mouse Model. Molecular Neurobiology, 2016, 53, 2276-2286.	1.9	8
24	Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21WAF1/CIP1 expression. Molecular Brain, 2015, 8, 54.	1.3	50
25	Enhancement of BACE1 Activity by p25/Cdk5-Mediated Phosphorylation in Alzheimerâ€™s Disease. PLoS ONE, 2015, 10, e0136950.	1.1	42
26	An early endosome regulator, Rab5b, is an LRRK2 kinase substrate. Journal of Biochemistry, 2015, 157, 485-495.	0.9	70
27	Reduction of Nfia gene expression and subsequent target genes by binge alcohol in the fetal brain. Neuroscience Letters, 2015, 598, 73-78.	1.0	13
28	Increased TRPC5 glutathionylation contributes to striatal neuron loss in Huntingtonâ€™s disease. Brain, 2015, 138, 3030-3047.	3.7	83
29	LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase. Nature Communications, 2015, 6, 8255.	5.8	79
30	Increased DJ-1 in Urine Exosome of Korean Males with Parkinsonâ€™s Disease. BioMed Research International, 2014, 2014, 1-8.	0.9	72
31	miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. Neurobiology of Aging, 2014, 35, 1712-1721.	1.5	120
32	JMJD2A attenuation affects cell cycle and tumourigenic inflammatory gene regulation in lipopolysaccharide stimulated neuroectodermal stem cells. Experimental Cell Research, 2014, 328, 361-378.	1.2	11
33	Prediction of miRNA-mRNA associations in Alzheimerâ€™s disease mice using network topology. BMC Genomics, 2014, 15, 644.	1.2	25
34	Systemic injection of LPS induces region-specific neuroinflammation and mitochondrial dysfunction in normal mouse brain. Neurochemistry International, 2014, 69, 35-40.	1.9	151
35	Baclofen, a GABAB receptor agonist, enhances ubiquitin-proteasome system functioning and neuronal survival in Huntingtonâ€™s disease model mice. Biochemical and Biophysical Research Communications, 2014, 443, 706-711.	1.0	37
36	Age-dependent effects of valproic acid in Alzheimerâ€™s disease (AD) mice are associated with nerve growth factor (NGF) regulation. Neuroscience, 2014, 266, 255-265.	1.1	33

#	Article	IF	Citations
37	Identification of cancer-specific biomarkers by using microarray gene expression profiling. Biochip Journal, 2013, 7, 57-62.	2.5	9
38	Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinsonâ€™s Disease. Science Translational Medicine, 2012, 4, 141ra90.	5.8	444
39	The hAPPâ€¥AC transgenic model has elevated UPS activity in the frontal cortex similar to Alzheimerâ€™s disease and Downâ€™s syndrome. Journal of Neurochemistry, 2010, 114, 1819-1826.	2.1	13
40	Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. Human Molecular Genetics, 2008, 17, 3144-3153.	1.4	35
41	Proteasome Activator Enhances Survival of Huntington's Disease Neuronal Model Cells. PLoS ONE, 2007, 2, e238.	1.1	110
42	Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Experimental Neurology, 2005, 193, 469-480.	2.0	106
43	Generalized brain and skin proteasome inhibition in Huntington's disease. Annals of Neurology, 2004, 56, 319-328.	2.8	164
44	Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends in Neurosciences, 2002, 25, 79-84.	4.2	181
45	Spatial memory testing decreases hippocampal amyloid precursor protein in young, but not aged, female rats. Neuroscience Letters, 2002, 328, 50-54.	1.0	26
46	A direct role of the homeodomain proteins Phox2a/2b in noradrenaline neurotransmitter identity determination. Journal of Neurochemistry, 2002, 80, 905-916.	2.1	41
47	Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice. European Journal of Neuroscience, 2002, 15, 498-506.	1.2	25